Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging

Clinical Effectiveness of Pharmacologic Stress Radionuclide Myocardial Perfusion Imaging as a Guide to Management of Patients With Known CAD: Comparison of Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00976053

Enrollment

330

Registered

2009-09-14

Start date

2009-06-30

Completion date

2014-10-31

Last updated

2014-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Myocardial perfusion imaging, Single photon emission computed tomography, Positron emission tomography

Brief summary

The purpose of this study is to compare pharmacologic stress myocardial perfusion PET with pharmacologic stress myocardial perfusion SPECT in a near-simultaneous, head-to-head comparison in the same patient. The investigators hypothesize that pharmacologic stress myocardial perfusion PET will prove superior to pharmacologic stress myocardial perfusion SPECT as a first-line diagnostic test for higher-risk patients with known coronary artery disease (CAD) who present with symptoms consistent with possible worsening of their CAD.

Interventions

PROCEDUREMyocardial perfusion imaging

Randomization assignment to one of SPECT or PET myocardial perfusion imaging

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 90 Years

Healthy volunteers

Inclusion criteria

* History of coronary artery disease * New or worsening symptoms * Out-patients and in-hospital patients

Exclusion criteria

* Creatinine above 2.5 mg% * PCI within prior 6 months * Pregnant females * Cardiomyopathy (LVEF below 40%) * Significant valvular heart disease * Body mass index greater than 38

Design outcomes

Primary

Measure	Time frame
Diagnostic failure of SPECT vs PET	60 days

Secondary

Measure	Time frame
Composite of diagnostic or clinical failure	12 months
Each of individual components of clinical failure	12 months
Relative effect on quality of life	3 months, 6 months
Relative direct and downstream costs	3 months, 6 months, 12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026